Biotech Intelligence
Track CRISPR Deal Flow Without Reading 500 Preprints a Week
A twice-monthly brief built for VC scouts and associates tracking gene-editing opportunities.
bioRxiv publishes 500+ life sciences preprints weekly. You can't read them all — and the ones that matter for your portfolio rarely announce themselves loudly. CRISPR Brief does the screening so you don't have to.
The Problem
- Screening CRISPR preprints takes 2–4 hours per week you don't have
- Generic biotech newsletters optimize for opens, not for deal-relevant signal
- A $500/mo analyst is overkill for preprint monitoring but worth it for full diligence
- You occasionally miss a relevant Phase I IND or preclinical readout — and find out too late
What CRISPR Brief Delivers
- 1 bioRxiv preprint per issue — synthesized with VC framing and competitive landscape context
- 1 FDA filing event per issue — clinical milestone tracking and strategic relevance
- 1 company pipeline update per issue — key diligence flags for gene-editing plays
- Published every other Thursday — no noise, no sponsored content
- Pseudonymous author — no personal brand required, no identity disclosure to subscribers
See the Quality Before You Subscribe
Sample Issue — VERVE Therapeutics
VERVE-101 IND clearance for HeFH — what to watch in Phase 1b
This was a live diligence-relevant event. CRISPR Brief's issue included: mechanism of action comparison vs. incumbents, Phase I dose-selection risk, and a competitive landscape map of the HeFH indication. Issue Zero is freely readable before you commit.
→ Read Issue Zero — no account needed
Pricing
CRISPR Brief is operated pseudonymously. Your subscription records are never tied to your firm or institutional email. The author's functional-genomics background is demonstrated through analytical framing and citations — not personal biography.